Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

H. Rosing; W.W. ten Bokkel Huinink; R. van Gijn; R.F.M. Rombouts; A. Bult; J.H. Beijnen

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

H. Rosing, W.W. ten Bokkel Huinink, R. van Gijn, R.F.M. Rombouts, A. Bult, J.H. Beijnen

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	69-77
Number of pages	8
Journal	European Journal of Drug Metabolism and Pharmacokinetics
Volume	24
Publication status	Published - 1999

Keywords

Farmacie/Biofarmaceutische wetenschappen (FARM)
Medical technology
Farmacie(FARM)
Biomedische technologie en medicijnen
Public Health
Analytical chemistry
Drugmisbruik en verslaving

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Rosing, H., ten Bokkel Huinink, W. W., van Gijn, R., Rombouts, R. F. M., Bult, A., & Beijnen, J. H. (1999). Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). European Journal of Drug Metabolism and Pharmacokinetics, 24, 69-77.

Rosing, H. ; ten Bokkel Huinink, W.W. ; van Gijn, R. et al. / Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). In: European Journal of Drug Metabolism and Pharmacokinetics. 1999 ; Vol. 24. pp. 69-77.

@article{a440da92467943dcb5e463df21a658b0,

title = "Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)",

keywords = "Farmacie/Biofarmaceutische wetenschappen (FARM), Medical technology, Farmacie(FARM), Biomedische technologie en medicijnen, Public Health, Analytical chemistry, Drugmisbruik en verslaving",

author = "H. Rosing and {ten Bokkel Huinink}, W.W. and {van Gijn}, R. and R.F.M. Rombouts and A. Bult and J.H. Beijnen",

year = "1999",

language = "Undefined/Unknown",

volume = "24",

pages = "69--77",

journal = "European Journal of Drug Metabolism and Pharmacokinetics",

issn = "0378-7966",

publisher = "Adis",

}

Rosing, H, ten Bokkel Huinink, WW, van Gijn, R, Rombouts, RFM, Bult, A & Beijnen, JH 1999, 'Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)', European Journal of Drug Metabolism and Pharmacokinetics, vol. 24, pp. 69-77.

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). / Rosing, H.; ten Bokkel Huinink, W.W.; van Gijn, R. et al.
In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 24, 1999, p. 69-77.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

AU - Rosing, H.

AU - ten Bokkel Huinink, W.W.

AU - van Gijn, R.

AU - Rombouts, R.F.M.

AU - Bult, A.

AU - Beijnen, J.H.

PY - 1999

Y1 - 1999

KW - Farmacie/Biofarmaceutische wetenschappen (FARM)

KW - Medical technology

KW - Farmacie(FARM)

KW - Biomedische technologie en medicijnen

KW - Public Health

KW - Analytical chemistry

KW - Drugmisbruik en verslaving

M3 - Article

SN - 0378-7966

VL - 24

SP - 69

EP - 77

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

ER -

Rosing H, ten Bokkel Huinink WW, van Gijn R, Rombouts RFM, Bult A, Beijnen JH. Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). European Journal of Drug Metabolism and Pharmacokinetics. 1999;24:69-77.